
Treatment GuideJust DiagnosedSex & DatingAfrican AmericanStigmaAsk the HIV DocPrEP En EspañolNewsVoicesPrint IssueVideo
CONTACTCAREER OPPORTUNITIESADVERTISE WITH USPRIVACY POLICYPRIVACY PREFERENCESTERMS OF USELEGAL NOTICE
© 2023 Pride Publishing Inc.
All Rights reserved
All Rights reserved
Scroll To Top
By continuing to use our site, you agree to our Private Policy and Terms of Use.
While the majority of HIVers on successful antiretroviral therapy regimens post significant -- even complete -- immune system recovery, not everyone can expect such robust results, warns a study from the journal Clinical Infectious Diseases. Researchers followed for 7.5 years more than 350 HIV-positive men and women who had achieved significant viral suppression through anti-HIV drugs (identified as viral loads held below 1,000 copies for at least four years) and found that the study participants who began treatment with higher CD4-cell counts also achieved the highest CD4 rebounds. Ninety-five percent of participants who began anti-HIV treatment with a CD4-cell count about 300 achieved a 'near normal' count of 500 cells or higher, compared to just 44% of those starting medications with a CD4-cell count under 100 and 25% of those starting therapy with a count between 100 and 200. In some cases, HIVers who began therapy with low T-cell counts did not achieve full immune system recovery after 10 years of otherwise successful antiretroviral treatment. The analysis also showed that the greatest CD4-cell gains occurred within the first four years of treatment, with much slower improvements thereafter. 'Although the majority of patients have evidence of slow CD4-cell count over time, many do not,' the Emory University researchers concluded. 'These individuals may have an elevated risk of non-AIDS-related morbidity and mortality.'
From our Sponsors
Most Popular
Plus: Featured Video